| 臺大學術典藏 |
2021-02-18T08:38:06Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chieh-Chang Chen; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2021-02-18T08:38:05Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chieh-Chang Chen; Chang C.-Y.; Chen M.-J.; CHIEN-CHUAN CHEN; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-18T08:38:05Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chieh-Chang Chen; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-18T08:38:04Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; CHIEN-CHUAN CHEN; Chieh-Chang Chen; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-18T08:38:01Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chien-Chuan Chen; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-03T03:56:19Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; HAN-MO CHIU; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:30Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.;Chen C.-C.;Chen M.-J.;Chen C.-C.;Chang C.-Y.;Fang Y.-J.;Lee J.-Y.;Hsu S.-J.;Luo J.-C.;Chang W.-H.;Hsu Y.-C.;Tseng C.-H.;Tseng P.-H.;Wang H.-P.;Yang U.-C.;Shun C.-T.;Lin J.-T.;Yi-Chia Lee;Wu M.-S.; Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; YI-CHIA LEE; Wu M.-S. |
| 臺大學術典藏 |
2021-02-02T05:45:22Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.;Chang C.-Y.;Chen M.-J.;Chen C.-C.;Fang Y.-J.;Lee J.-Y.;Wu J.-Y.;Luo J.-C.;Liou T.-C.;Chang W.-H.;Tseng C.-H.;Wu C.-Y.;Yang T.-H.;Chang C.-C.;Wang H.-P.;Sheu B.-S.;Lin J.-T.;Bair M.-J.;Wu M.-S.;Tai C.-M.;Lee C.-T.;Wang W.-L.;Yi-Chia Lee;Wang Y.-C.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; YI-CHIA LEE; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:19Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.;Bair M.-J.;Chen C.-C.;Yi-Chia Lee;Chen M.-J.;Chen C.-C.;Tseng C.-H.;Fang Y.-J.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Wu J.-Y.;Chang W.-H.;Chang C.-C.;Chen C.-Y.;Chen P.-Y.;Shun C.-T.;Hsu W.-F.;Hung H.-W.;Lin J.-T.;Chang C.-Y.;Wu M.-S.; Liou J.-M.; Bair M.-J.; Chen C.-C.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2021-02-02T05:45:16Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.;Chen C.-C.;Chang C.-Y.;Chen M.-J.;Chen C.-C.;Fang Y.-J.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Wu J.-Y.;Liou T.-C.;Chang W.-H.;Hsu Y.-C.;Tseng C.-H.;Chang C.-C.;Bair M.-J.;Liu T.-Y.;Hsieh C.-F.;Tsao F.-Y.;Shun C.-T.;Lin J.-T.;Yi-Chia Lee;Wu M.-S.;The Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; YI-CHIA LEE; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:15Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.;Fang Y.-J.;Chen C.-C.;Bair M.-J.;Chang C.-Y.;Yi-Chia Lee;Chen M.-J.;Chen C.-C.;Tseng C.-H.;Hsu Y.-C.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Chang C.-C.;Chen C.-Y.;Chen P.-Y.;Shun C.-T.;Hsu W.-F.;Hu W.-H.;Chen Y.-N.;Sheu B.-S.;Lin J.-T.;Wu J.-Y.;El-Omar E.M.;Wu M.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:09Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; YI-CHIA LEE; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:08Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; YI-CHIA LEE; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T05:45:08Z |
The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus
|
Cheng H.-C.;Liou J.-M.;Luo J.-C.;Chiu C.-T.;Wu M.-S.;Yi-Chia Lee;Wu C.-Y.;Wu D.-C.;Hsu P.-I.;Chang C.-C.;Chang W.-L.;Lin J.-T.;Sheu B.-S.; Cheng H.-C.; Liou J.-M.; Luo J.-C.; Chiu C.-T.; Wu M.-S.; YI-CHIA LEE; Wu C.-Y.; Wu D.-C.; Hsu P.-I.; Chang C.-C.; Chang W.-L.; Lin J.-T.; Sheu B.-S. |
| 臺大學術典藏 |
2021-02-02T02:25:00Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:37Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:19Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; MING-SHIANG WU; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:17Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:14Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:08Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:08Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:01Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; MING-SHIANG WU; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus
|
Cheng H.-C.; Liou J.-M.; Luo J.-C.; Chiu C.-T.; MING-SHIANG WU; Lee Y.-C.; Wu C.-Y.; Wu D.-C.; Hsu P.-I.; Chang C.-C.; Chang W.-L.; Lin J.-T.; Sheu B.-S. |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:43Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:39Z |
Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
|
Fang Y.-J.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Yu C.-C.; Chiu M.-C.; Kuo C.-C.; Weng Y.-J.; Bair M.-J.; MING-SHIANG WU; Luo J.-C.; Liou J.-M. |
| 臺大學術典藏 |
2021-01-15T03:46:54Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; HSIU-PO WANG; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2021-01-15T03:46:42Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; HSIU-PO WANG; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-01-15T03:46:41Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; HSIU-PO WANG; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:40Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chen M.-J.; Chien-Chuan Chen; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chien-Chuan Chen; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; CHIEH-CHANG CHEN; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Tsao F.-Y.; Liu T.-Y.; Hsieh C.-F.; Bair M.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-Y.; Chen M.-J.; Chien-Chuan Chen; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C. |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEH-CHANG CHEN; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:37Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEH-CHANG CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chien-Chuan Chen; CHIEH-CHANG CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHIEH-CHANG CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chun-Chao Chang; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:33Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chien-Chuan Chen; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
CHIEH-CHANG CHEN; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:31Z |
Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
|
Fang Y.-J.; Chen M.-J.; CHIEH-CHANG CHEN; Lee J.-Y.; Yang T.-H.; Yu C.-C.; Chiu M.-C.; Kuo C.-C.; Weng Y.-J.; Bair M.-J.; Wu M.-S.; Luo J.-C.; Liou J.-M. |
| 臺大學術典藏 |
2020-11-02T02:04:47Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
MING-SHIANG WU; Lee Y.-C.; Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-02T02:04:33Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Lee Y.-C.; Wang W.-L.; Lee C.-T.; Tai C.-M.; MING-SHIANG WU; Bair M.-J.; Lin J.-T.; Sheu B.-S.; Wang H.-P.; Chang C.-C.; Yang T.-H.; Wu C.-Y.; Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; Wang Y.-C. |
| 臺大學術典藏 |
2020-11-02T02:04:26Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Helicobacter Consortium; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU; the Taiwan Gastrointestinal Disease; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C. |
| 臺大學術典藏 |
2020-11-02T02:04:25Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium; Chang C.-C.; Luo J.-C.; Yang T.-H.; Lee J.-Y.; Hsu Y.-C.; Chen C.-C.; Tseng C.-H.; Chen M.-J.; Lee Y.-C.; Chang C.-Y.; Bair M.-J.; Chen C.-C.; Fang Y.-J.; Liou J.-M. |
| 臺大學術典藏 |
2020-11-02T02:04:20Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; MING-SHIANG WU; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-02T02:04:19Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; MING-SHIANG WU; Bair M.-J.; Lee Y.-C.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G. |
| 臺大學術典藏 |
2020-11-02T02:04:13Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S. |
| 臺大學術典藏 |
2020-11-02T02:04:03Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Helicobacter Consortium; Taiwan Gastrointestinal Disease; MING-SHIANG WU; El-Omar E.M.; Chuang E.Y.; Lu T.-P.; Lin J.-T.; Wu J.-Y.; Chen Y.-N.; Hsu W.-F.; Chen C.-Y.; Luo J.-C.; Yang T.-H.; Lee J.-Y.; Chen C.-C.; Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J. |
